JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (5): 19-22.doi: 10.6040/j.issn.1671-7554.0.2016.1300

Previous Articles     Next Articles

Effects of gemigliptin on the therapeutic effect and inflammatory factors of monocrotaline-induced pulmonary arterial hypertension in rats

ZHANG Luan1, CHEN Ou2, LUAN Yun1, ZHU Xiaobo1, CHEN Yuan1, WANG Yibiao1   

  1. 1. Department of Pediatric, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    2. Department of Nursing, Shandong University, Jinan 250012, Shandong, China
  • Online:2017-05-10 Published:2017-05-10

PDF (PC)

129

Abstract: Objective To investigate the effects of gemigliptin on the therapeutic effect and inflammatory factors of monocrotaline(MCT)-induced pulmonary arterial hypertension(PAH)in rats. Methods A total of 40 Male SD rats were randomly divided into 3 groups: control group, MCT group and gemigliptin group. The pulmonary hypertension models were established by subcutaneous injection of MCT(60 mg/kg), and rats in the intervention group were treated with gemigliptin［150 mg/(kg·d)］ gavage for 28 days. After that, mean pulmonary artery pressure(mRVP), pulmonary arterial systolic pressure(RVSP), and right ventricular hypertrophy index(RVHI)were measured. The pulmonary vascular remodeling was assessed with HE staining. IL-1β and IL-6 were measured with ELISA. Results The mPAP, RVSP, RVHI and remodeling of the small arteries of the MCT group were significantly improved compared with those of the control group(P<0.001), and those of the gemigliptin group were significantly improved compared with those of the MCT group(P<0.001). The IL-6 level of MCT group was significantly higher than that of the control group(P=0.039), while it was lower of the gemigliptin group than of the MCT group(P=0.005). The IL-1β 山 东 大 学 学 报 (医 学 版)55卷5期 -张栾,等.Gemigliptin对野百合碱诱导的肺动脉高压大鼠治疗作用及炎症因子的影响 \=-level of the MCT group was significantly higher than that of the control group, while it was lower of the gemigliptin group than of the MCT group(P<0.001). Conclusion Gemigliptin may reduce the development of pulmonary hypertension by inhibiting pulmonary vascular inflammation.

Key words: Pulmonary arterial hypertension, Monocrotaline, Gemigliptin, Inflammatory reaction, IL-6, IL-1β

CLC Number: 

  • R574
[1] 蒋晓敏, 周陵, 陈绍良. 肺动脉高压肺血管丛状病变的研究进展[J]. 中国病理生理杂志, 2014, 30(8): 1519-1522. JIANG Xiaomin, ZHOU Ling, CHEN Shaoliang. Progress in plexiform lesion of pulmonary hypertension[J]. Chin J Pathophysiology, 2014, 30(8): 1519-1522.
[2] El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension[J]. Prog Cardiovasc Dis, 2012, 55(2): 218-228.
[3] Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV(DPP IV)inhibitor class for the treatment of Type 2 Diabetes[J]. Curr Drug Targets, 2009, 10(1): 71-87.
[4] Hwan HJ, Jung TW, Ryu JY, et al. Dipeptidyl petidase-IV inhibitor(gemigliptin)inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes[J]. Mol Cell Endocrinol, 2014, 392(1-2): 1-7.
[5] Matsuda Y, Hoshikawa Y, Ameshima S, et al. Effects of peroxisome proliferator-activated gamma ligands on monocrotaline-induced pulmonary hypertension in rats[J]. Nihon Kokyuki Gakkai Zasshi, 2005, 43(5): 283-288.
[6] Guignabert C, Tu L, Girerd B, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension importance of endothelial communication[J]. Chest, 2015, 147(2): 529-537.
[7] Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension[J]. Pharmacol Ther, 2014, 141(2): 172-191.
[8] Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension[J]. Circ Res, 2014, 115(1): 165-175.
[9] Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension a complex interplay[J]. Circulation, 2014, 129(12): 1332-1340.
[10] Tanino Y. Monocrotaline-induced pulmonary hypertension in animals[J]. Nihon Rinsho, 2001, 59(6): 1076-1080.
[11] Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1): 210-221.
[12] Bi LQ, Zhu R, Kong H, et al. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats[J]. Int Immunopharmacol, 2013, 16(1): 7-16.
[13] Tian W, Jiang X, Sung YK, et al. Leukotrienes in pulmonary arteria hypertension[J]. Immunol Res, 2014, 58(2-3): 387-393.
[14] Meloche J, Renard S, Provencher S, et al. Anti-inflammatory and immunosuppressive agents in PAH[J]. Handb Exp Pharmacol, 2013, 218: 437-476.
[15] Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss[J]. J Clin Invest, 2014, 124(10): 4473-4488.
[16] Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4(DPP4)beyond glucose control: potential implications in cardiovascular disease[J]. Atherosclerosis, 2013, 226(2): 305-314.
[17] Zhong J, Rao X, Deiuliis J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation[J]. Diabetes, 2013, 62(1): 149-157.
[18] Ta NN, Schuyler CA, Li Y, et al. DPP-4(CD26)inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice[J]. J Cardiovasc Pharmacol, 2011, 58(2): 157-166.
[19] Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice[J]. Diabetes, 2011, 60(4): 1246-1257.
[20] Reinhold D, Bank U, Bühling V, et al. Dipeptidyl peptidase IV(CD26)on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production[J]. Immunobiology, 1993, 188(4-5): 403-414.
[21] Choi SH, Park S, Oh CJ, et al. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation[J]. Vascul Pharmacol, 2015, 73: 11-19. doi: 10.1016/j.vph.2015.07.005.
[22] Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease[J]. Cell, 2010, 140(6): 900-917.
[1] ZHANG Yu, HAN Chen, WANG Zhaoxia, WANG Zhaopeng, ZHANG Yueying, ZHOU Shuping, MA Ranran, WANG Hengxiao. Protective effects of Tamarix chinensis Lour on mice with alcoholic liver injury and its mechanism [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 61-67.
[2] CHEN Hui, LI Heng, YUE Longtao, ZHANG Min, WANG Congcong, WANG Shan, ZHANG Peng, DUAN Ruisheng. Therapeutic effects of AG490 on experimental autoimmune myasthenia gravis in Lewis rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 11-16.
[3] LIU Zhengmei, JIANG qiong, ZHOU Jianjiang, GUAN Zhizhong, ZHAO Yan, XIONG Lin, XIE Yuan. Effect of Helicobacter pylori infection on NLRP3 inflammasome activation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 9-13.
[4] LIU Huimin, LIU Deng, LI Xiaoyu, ZOU Shufeng, JIANG Limin, LI Yuhuan. Effect of Lobelia alkaloids on endothelin-1 signal pathway in a rat model of pulmonary arterial hypertension [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 1-4.
[5] TANG Mengmeng, JIN Nüwa, LIU Chuanzhen, LIU Kai, CAO Guangqing, WANG He, PANG Xinyan, WU Shuming. Effects of ethyl pyruvate in the treatment of hyperkinetic pulmonary hypertension [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 75-80.
[6] WANG Ya-yun1, WANG Yi-biao1, ZHANG Xue1, LIN Mei1, SU Hong1, MA Yu1, ZHU Xiao-bo1, CHEN Ou2. Effect of PS-341 on expression of Nrf2/NF-κB in rats with pulmonary arterial hypertension and its mechanism [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(2): 6-11.
[7] ZHANG Zhaohua1, WANG Yibiao1, LUAN Yun2, SU Hong1, MA Yu1, LIN Mei1, SUN Ruopeng3 . Effect of mesenchymal stem cells implantation on experimental  impairment caused by pulmonary arterial hypertension in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(8): 31-.
[8] . Effect of nuclear factorκB inhibitor PDTC on pulmonary arterial hypertension [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(11): 55-58.
[9] SHI Ping,SUN Wen-yu,YANG Min. CRP, IL-6 and TNF-α in the pathogenesis of allograft arteriosclerosis in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(3): 258-262.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd